Using biosimilars as a way to reduce pharmaceutical expenditure was highlighted as a means to address this problem. However, the necessity of reducing the knowledge gap and building trust in biosimilars is still a key challenge.

Dr Paul Cornes (University Hospitals Bristol, NHS Foundation Trust, Bristol, UK) pointed out the fact that cancer medicine costs are increasing five times faster than any other class of medicine. Given the fact that by 2018, biologicals worth more than US$68 billion in current annual sales will lose patent protection [2], the case for using biosimilars seems clear.

Professor Arnold G Vulto (Erasmus University, Rotterdam, The Netherlands) highlighted the fact that the total medicine bill will grow exponentially with the introduction of so many blockbuster breakthrough medicines. He too pointed to the ‘savings potential of biosimilars medicines’. He suggests that one way to modify the increasing cost of medicine would be to increase the use of biosimilars.

Dr Niklas Ekman, a senior researcher at the Finnish Medicines Agency (FIMEA, Helsinki, Finland), gave a presentation on ‘Biosimilars from the perspective of an EU regulator’. He highlighted the fact that batch-to-batch variability is inherent for all biologicals, both for originators and biosimilars.

Dr Ekman also mentioned that FIMEA considers EU biosimilars interchangeable with their reference biologicals. Automatic substitution at the pharmacy level, however, is not included in the current FIMEA recommendation [3, 4]. He also pointed to similar positions that have been adopted by other EU national authorities, including the Medicines Evaluation Board (MEB) in The Netherlands, the Paul Ehrlich Institute (PEI) in Germany and the Health Products Regulatory Authority (HPRA) in Ireland.

Editor’s comment
This article for GaBI Online is a summary of the full article published in GaBI Journal.

If you would like to receive a copy* of the GaBI Journal manuscript [1], please send us an email. 

Readers interested to learn more about saving money in Europe with biosimilars are invited to visit www.gabi-journal.net to view the following manuscript published in GaBI Journal:

Saving money in the European healthcare systems with biosimilars

If you are interested in contributing a research paper in a similar area to GaBI Journal, please send us your submission here.

_{*For profit organizations subjected to a fee}

Related article
The Netherlands to track switching of biologicals

References
1. Derbyshire M. Reducing healthcare costs and building trust in biosimilar medicines. Generics and Biosimilars Initiative Journal (GaBI Journal). 2016;5(2):84-8. doi:10.5639/gabij.2016.0502.020
2. Derbyshire M. Patent expiry dates for best-selling biologicals. Generics and Biosimilars Initiative Journal (GaBI Journal). 2015;4(4):178-9. doi:10.5639/gabij.2015.0404.040
3. GaBI Online – Generics and Biosimilars Initiative. Finnish drug regulator recommends interchangeability of biosimilars [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2016 Aug 5]. Available from: www.gabionline.net/Policies-Legislation/Finnish-drug-regulator-recommends-interchangeability-ofbiosimilars
4. FIMEA. Interchangeability of biosimilars – position of Finnish Medicines Agency Fimea. 22 May 2015 [homepage on the Internet]. [cited 2016 Aug 5]. Available from: www.fi mea.fi /documents/542809/838272/29197_Biosimilaarien_vaihtokelpoisuus_EN.pdf

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2016 Pro Pharma Communications International. All Rights Reserved.